E Fund Management Co., Ltd. Agenus Inc Transaction History

E Fund Management Co., Ltd.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.12 - $1.88 $10,114 - $16,978	9,031 Added 11.68%	86,343 $98,000
Q2 2023 Aug 11, 2023	SELL	$1.31 - $2.04 $60,966 - $94,939	-46,539 Reduced 37.58%	77,312 $124,000
Q1 2023 May 11, 2023	BUY	$1.45 - $2.95 $46,607 - $94,821	32,143 Added 35.05%	123,851 $188,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $3.25 $8,409 - $13,529	-4,163 Reduced 4.34%	91,708 $220,000
Q3 2022 Nov 14, 2022	SELL	$1.96 - $3.14 $33,257 - $53,279	-16,968 Reduced 15.04%	95,871 $197,000
Q2 2022 Aug 15, 2022	BUY	$1.3 - $2.64 $70,565 - $143,301	54,281 Added 92.7%	112,839 $219,000
Q1 2022 May 12, 2022	BUY	$2.35 - $3.47 $11,674 - $17,238	4,968 Added 9.27%	58,558 $144,000
Q4 2021 Feb 11, 2022	BUY	$2.92 - $5.74 $79,047 - $155,387	27,071 Added 102.08%	53,590 $173,000
Q3 2021 Nov 12, 2021	SELL	$4.98 - $6.63 $2,958 - $3,938	-594 Reduced 2.19%	26,519 $139,000
Q1 2021 May 12, 2021	BUY	$2.69 - $5.25 $72,933 - $142,343	27,113 New	27,113 $73,000

2.07M

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.